ARA-290 vs Epithalon

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

ARA 290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin (EPO), engineered to activate the innate repair receptor (IRR) — a tissue-protective heteroreceptor complex comprising the EPO receptor and the β-common receptor (CD131) — without engaging the classical erythropoietic EpoR homodimer, thereby separating EPO's tissue-protective signaling from its hematopoietic effects. By selectively engaging the IRR rather than the erythropoietic receptor, cibinetide activates anti-inflammatory and anti-apoptotic intracellular pathways in neurons, endothelium, and other metabolically active tissues without causing erythrocytosis, hypertension, or thrombosis, making it a candidate for neuropathy and inflammatory tissue injury contexts. Randomized, double-blind Phase 2 clinical trials have demonstrated that cibinetide improves metabolic control and neuropathic symptom scores in patients with type 2 diabetes, and a separate study demonstrated improved corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy — providing human proof-of-concept for both diabetic and inflammatory peripheral neuropathy applications. Cibinetide (ARA 290) is an investigational compound that has not received FDA approval for any indication; Phase 2 data supports further investigation in peripheral neuropathies, but no Phase 3 completion or regulatory filing has occurred as of 2025.

Epithalon is believed to activate telomerase, the enzyme responsible for maintaining telomere length, with several in vitro and animal studies reporting telomere elongation. It also appears to regulate the expression of p53 and other cell-cycle control genes, modulate the hypothalamic-pituitary axis via pineal gland activity, and upregulate antioxidant defences including superoxide dismutase and catalase.

Epithalon (Ala-Glu-Asp-Gly; AEDG peptide) is a synthetic tetrapeptide developed by Vladimir Khavinson as a more stable analog of the native pineal tetrapeptide epithalamin, proposed to restore physiological circadian rhythm regulation and telomerase activity in aging cells, and to exert broad anti-aging effects through epigenetic gene expression modulation in pineal and other tissues. Epithalon is proposed to activate telomerase and modulate telomere maintenance in aging somatic cells, normalize melatonin production and the neuroendocrine-immune axis, and restore physiological parameters that decline with aging; in vitro studies and preclinical animal models provide mechanistic support for these effects. Published human studies from the Khavinson group include a controlled clinical trial demonstrating epithalon's effects on retinal function in retinitis pigmentosa patients and observational data showing melatonin rhythm normalization in elderly subjects, representing the strongest indexed clinical evidence specifically for epithalon; both studies are formally indexed in PubMed. Epithalon has no FDA approval and no approved indication in any Western jurisdiction; published clinical evidence derives from a single research group without external independent replication by standard Western trial methodology, and while the mechanistic and observational research is indexed in peer-reviewed journals, the evidence base does not meet the threshold for established efficacy in any recognized clinical condition. Epithalon dosage protocols: no human clinical trial has established a standardized dosing regimen for epithalon. The published Khavinson clinical research does not report specific dose-response data in a format translatable to general dosing guidance. Research protocols and anecdotal bodybuilding and anti-aging community practice commonly reference epithalon at doses of 5–10mg per injection administered subcutaneously, with course lengths of 10–20 consecutive daily injections repeated one to two times per year — a pattern derived from the animal research and the Khavinson group's general bioregulator protocol framework, not from a dose-ranging clinical trial. Intranasal delivery has also been explored due to direct CNS access via the olfactory pathway. Epithalon is a research compound with no approved clinical dosing guidelines in any jurisdiction; all dosing references reflect preclinical and anecdotal research contexts only.